Scholars Central

Conference abstractPublished 2022

New Glp1a and Diabetes controlle

Authors: Hazem Rayyan

King Salman Military Hospital-Tabuk, Saudi Arabia

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

The glucagon-like peptide-1 receptor agonist (GLP-1RA) semaglutide is the most recently approved agent of this drug class, and the only GLP-1RA currently available as both subcutaneous and oral formulation. While GLP-1RAs effectively improve glycemic control and cause weight loss, potential safety concerns have arisen over the years. For semaglutide, such concerns have been addressed in the extensive phase 3 registration trials including cardiovascular outcome trials for both subcutaneous (SUSTAIN: Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes) and oral (PIONEER: Peptide InnOvatioN for the Early diabEtes tReatment) semaglutide and are being studied in further trials and registries, including real world data studies. In SUSTAIN programme, Semaglutide was associated with consistent reductions in HbA1c and higher proportions of subjects achieving glycaemic targets of <7.0% and ≤6.5%, vs comparators. In SUSTAIN 6, Semaglutide treated patients experienced a significant 26% risk reduction in the primary composite outcome. Given the beneficial metabolic and cardiovascular actions of semaglutide, and the low risk for severe adverse events, semaglutide has an overall favorable risk/benefit profile for patient with type 2 diabetes.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Endocrinology & Diabetes Research.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalEndocrinology & Diabetes Research
  • SubjectDiabetes & Endocrinology
  • BylineArticles whose byline prints “Hazem Rayyan”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels